Early Diagnosis with 11-Gene Panel Screening for Non Small Cell Lung Cancer

NSCLC, caused by various mutations in a spectrum of cancer driver genes, could be early diagnosed by genetic screening and may have corresponding drug responses. In an effort to complete the clinical application of precision diagnosis in lung cancer, increase the confirmed diagnostic rate and also provide the reference and inspiration for precision diagnosis of other tumors. We designed a panel of 11 genes, BRAF, EGFR, KRAS, HRAS, IDH, PIK3CA, RET, PTEN, C-KIT, SMAD4 and HER2, which played important roles in the progression of lung cancer to help diagnosis lung cancer. The results showed that compared with the healthy controls, the concentrations of BRAF, EGFR, KRAS, HRAS, IDH, PIK3CA, PTEN, C-KIT, SMAD4 and HER2 were higher in patients with benign lesions and lung cancer. There were significant difference between healthy controls and patients with lung cancer, also between patients with benign lesion and patients with lung cancer in the concentration of BRAF, EGFR, KRAS, HRAS, IDH, PIK3CA, C-KIT, SMAD4 and HER2, and there was no difference between healthy controls and patients with benign lesion. ROC analysis was further performed to evaluate the diagnosis efficiency. Sensitivity and Specificity of BRAF, EGFR, KRAS, IDH and SMAD4 was much higher and with the combination of these genes, that is the panel, the sensitivity was 100%. The area under the curve of BRAF, EGFR, KRAS, IDH, SMAD4 and the panel was 0.786, 0.803, 0.87, 0.906, 0.887 and 1.000 respectively. The panel of these 11 genes is of great clinical value for diagnosis of lung cancer and target therapy for that it expanded the coverage of mutated gene and improved the diagnostic efficiency.